Insulin Detemir Causes Lesser Weight Gain in Comparison to Insulin Glargine: Role on Hypothalamic NPY and Galanin

Influence of Baseline Glycemia on Outcomes With Insulin Glargine Use in Patients Uncontrolled on Oral Agents

(2014) Mary Ann Banerji et al.   POSTGRADUATE MEDICINE

Effect of insulin analogues on risk of severe hypoglycaemia in patients with type 1 diabetes prone to recurrent severe hypoglycaemia (HypoAna trial): a prospective, randomised, open-label, blinded-endpoint crossover trial

(2014) Ulrik Pedersen-Bjergaard et al.   Lancet Diabetes & Endocrinology

Peptides and Food Intake

(2014) Carmen Sobrino Crespo et al.   Frontiers in Endocrinology

Pharmacodynamics of the long-acting insulin analogues detemir and glargine following single-doses and under steady-state conditions in patients with type 1 diabetes

(2013) G. Koehler et al.   DIABETES OBESITY & METABOLISM

Prevalence and Control of Diabetes in Chinese Adults

(2013) Yu Xu   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

A randomized trial comparing perinatal outcomes using insulin detemir or neutral protamine Hagedorn in type 1 diabetes

(2013) Moshe Hod et al.   Journal of Maternal-Fetal & Neonatal Medicine

The Effect of Excess Weight Gain With Intensive Diabetes Mellitus Treatment on Cardiovascular Disease Risk Factors and Atherosclerosis in Type 1 Diabetes Mellitus

(2012) Jonathan Q. Purnell et al.   CIRCULATION

Galanin and its receptors: A novel strategy for appetite control and obesity therapy

(2012) Penghua Fang et al.   PEPTIDES

Euglycemic Infusion of Insulin Detemir Compared With Human Insulin Appears to Increase Direct Current Brain Potential Response and Reduces Food Intake While Inducing Similar Systemic Effects

(2010) M. Hallschmid et al.   DIABETES

Perinatal Outcomes in Pregnancies Managed with Antenatal Insulin Glargine

(2009) Robert Egerman et al.   AMERICAN JOURNAL OF PERINATOLOGY

Insulin Glargine versus Neutral Protamine Hagedorn Insulin for Treatment of Diabetes in Pregnancy

(2008) Jennifer Smith et al.   AMERICAN JOURNAL OF PERINATOLOGY

A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes

(2008) Priscilla Hollander et al.   CLINICAL THERAPEUTICS

A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes

(2008) J. Rosenstock et al.   DIABETOLOGIA